Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)

British Journal of Anaesthesia

Volumn 116, Issue 2, 2016, Pages 233-240

  Kaufhold, N ^a   Schaller, S J ^a   Stauble C G ^a   Baumuller E ^a   Ulm, K ^b   Blobner, M ^a   Fink, H ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

neostigmine; neuromuscular block; quantitative neuromuscular monitoring; reversal neuromuscular block; rocuronium; sugammadex

Indexed keywords

NEOSTIGMINE; ROCURONIUM; SODIUM CHLORIDE; SUGAMMADEX; ANDROSTANE DERIVATIVE; CHOLINESTERASE INHIBITOR; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; ELECTROMYOGRAM; ELECTROMYOGRAPHY; ENDOTRACHEAL INTUBATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; NEUROMUSCULAR MONITORING; NEUROMUSCULAR TRANSMISSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANESTHETIC RECOVERY; ANTAGONISTS AND INHIBITORS; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTANOLS; ANESTHESIA RECOVERY PERIOD; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROMYOGRAPHY; FEMALE; GAMMA-CYCLODEXTRINS; HUMANS; MALE; MIDDLE AGED; NEOSTIGMINE; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR MONITORING; NEUROMUSCULAR NONDEPOLARIZING AGENTS; SODIUM CHLORIDE; YOUNG ADULT;

EID: 84961926405     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aev437     Document Type: Article

References (30)

1. Bom A, BradleyM, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41: 266-70
2. Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009; 110: 1020-5
3. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109: 816-24
4. Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol 2010; 27: 874-81
5. Pongracz A, Szatmari S, Nemes R, Fulesdi B, Tassonyi E. Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation. Anesthesiology 2013; 119: 36-42
6. Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology 2010; 113: 1054-60
7. Kim KS, Cheong MA, Lee HJ, Lee JM. Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia. Anesth Analg 2004; 99: 1080-5
8. Kopman AF. Tactile evaluation of train-of-four count as an indicator of reliability of antagonism of vecuronium-or atracurium-induced neuromuscular blockade. Anesthesiology 1991; 75: 588-93
9. Lien CA, Belmont MR, Abalos A, Hass D, Savarese JJ. The nature of spontaneous recovery from mivacurium-induced neuromuscular block. Anesth Analg 1999; 88: 648-53
10. Kirkegaard H, Heier T, Caldwell JE. Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block. Anesthesiology 2002; 96: 45-50
11. Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth 2008; 100: 622-30
12. de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007; 107: 239-44
13. Puhringer FK, Rex C, Sielenkamper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008; 109: 188-97
14. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium-or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007; 106: 283-8
15. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006; 104: 667-74
16. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007; 104: 555-62
17. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 106: 935-43
18. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modeling. J Roy Stat Soc C-Appl 1994; 43: 429-67
19. Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009; 110: 284-94
20. Ploeger BA, Smeets J, Strougo A, et al. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology 2009; 110: 95-105
21. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II. The Stockholm revision. Acta Anaesthesiol Scand 2007; 51: 789-808
22. Medical Research Council. Aids to the Examination of the Peripheral Nervous System. Memorandum No. 45. London: Her Majesty's Stationary Office, 1976
23. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015; 162: W1-73
24. Akaike H, ed. Information Theory and an Extension of theMaximum Likelihood Principle. Budapest: Akademiai Kiado, 1973
25. Harrell FE Jr. Regression Modeling Strategies. New York: Springer-Verlag, 2001
26. Payne JP, Hughes R, Al Azawi S. Neuromuscular blockade by neostigmine in anaesthetized man. Br J Anaesth 1980; 52: 69-76
27. Plaud B, Debaene B, Donati F, Marty J. Residual paralysis after emergence from anesthesia. Anesthesiology 2010; 112: 1013-22
28. Kotake Y, Ochiai R, Suzuki T, et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg 2013; 117: 345-51
29. Paton WD,Waud DR. The margin of safety of neuromuscular transmission. J Physiol (Lond) 1967; 191: 59-90
30. Duvaldestin P, Kuizenga K, Saldien V, et al. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium-or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010; 110: 74-82